GREY:IPHAF - Post by User
Post by
snrkidon Mar 24, 2008 9:46am
229 Views
Post# 14762614
Roche agreement
Roche agreementI have posted for a long time my personal feeling about Roche and their motivations when they deal with small JV partners. Roche has been a drag to the development of ISA247 right from beginning and I have posted my personal desire to see them go away. Latest indications are that Roche is still very much in the picture and is attempting to get back at least some of the non transplant indications.
I hope Isotechnika will resist that attempt and either go to another major partner or go alone in Psoriasis, Arthritil etc indications. They can also out license other indications piece by piece and just watch from sidelines.
Latest additions to the staff and board show the build-up of strong industry experience and knowlege being added. At present market at the stage Renal development is right now it is worth much more than $250 million Roche agreement promises.
have a great day...
snrkid.